Posted by: Northwest Eye in laser trabeculoplasty on September 15, 2025
How laser trabeculoplasty lowers eye pressure
Laser trabeculoplasty lowers eye pressure by directing laser energy at the trabecular meshwork, the drainage tissue in the front of your eye. The treatment can improve the flow of fluid out of the eye. Lower pressure can reduce stress on the optic nerve, which carries visual signals to the brain. When fluid does not drain properly, pressure can build and damage the optic nerve. Untreated glaucoma may lead to blindness.
SLT uses low-frequency laser energy on selected cells while leaving other portions of the drainage tissue intact. The goal is to stimulate better fluid outflow rather than remove the tissue. Laser treatment may be used first or added to another treatment for primary open-angle glaucoma.
These laser procedures are not all the same. The argon procedure is performed in an office, usually takes less than 10 minutes, and rarely causes discomfort. A topical glaucoma drop such as brimonidine may be given 15 minutes before argon treatment to help prevent a pressure rise. Those details apply to argon treatment, not automatically to SLT.
Which eye findings may affect whether it is considered
Open-angle glaucoma is the main setting in which laser trabeculoplasty is considered. The drainage angle must be visible so the ophthalmologist can aim at the trabecular meshwork. Angle-closure glaucoma is usually not treated with this procedure because the angle cannot be seen clearly enough for treatment.
People with primary open-angle, pigmentary, or pseudoexfoliation glaucoma tend to respond well to laser trabeculoplasty. Trauma-related or aphakic glaucoma may not respond as well as primary open-angle glaucoma. Aphakia means the eye does not have its natural lens or an implanted replacement lens. These patterns guide a discussion; they do not decide your treatment by themselves.
SLT can also help some people who already use glaucoma drops. The eye should be quiet before treatment. Active inflammation inside the eye is considered unsuitable for SLT because laser treatment may worsen the inflammation. SLT is traditionally not used for neovascular glaucoma.
Gonioscopy is the examination used to inspect your drainage tissue and angle. Your doctor also considers how much the tissue is pigmented. Densely pigmented drainage tissue tends to respond better because pigment helps absorb laser energy. Lightly pigmented tissue may need more laser energy and may be less successful.
A dense clouding that prevents the drainage tissue from being seen may make SLT unsafe or ineffective. Your doctor also considers whether the pressure is already high, how much optic-nerve damage exists, and whether the eye can tolerate a temporary pressure rise. Treatment may cover 180 degrees or 360 degrees of the drainage angle, depending on the plan.
How your pressure goal shapes the treatment plan
Glaucoma treatment aims to keep pressure in a target range while keeping the optic nerve, retinal nerve fiber layer, and visual fields stable. Your target is an estimate that your eye doctor may individualize or adjust as the disease changes.
For some patients, the initial target may be at least 25% lower than the pressure measured before treatment. A lower target may be chosen when optic-nerve damage is severe, the disease is progressing quickly, or other risk factors are present. The 25% figure is a starting benchmark for some patients, not a universal target for every eye.
Laser trabeculoplasty may be used as initial treatment or added to another treatment for primary open-angle glaucoma. Treatment may cover 180 degrees or 360 degrees of the drainage angle. The choice depends on the pressure goal and the condition of the drainage tissue.
Advanced or end-stage glaucoma can change the balance. A person with end-stage disease may not tolerate the possible pressure rise after laser and may instead need filtering surgery. Ask how much pressure reduction your optic nerve needs, how quickly that reduction is needed, and how your doctor will respond if laser treatment does not reach the target.
What happens during the laser visit
The laser visit usually takes place in an ophthalmologist’s office or an outpatient surgery center. Your eye pressure is checked, and numbing drops are used. No injections or needles are used for the preparation described in the cited patient guide.
A special contact lens is placed on your eye to help the ophthalmologist see and focus on the drainage angle. During SLT, the ophthalmologist directs quick laser pulses at selected cells in the trabecular meshwork while leaving other portions intact. One patient guide describes approximately 100 laser pulses through a special mirrored lens.
The laser treatment itself takes only a few minutes. Another patient guide describes treatment as five to ten minutes per eye. Plan for approximately two hours overall when preparation and follow-up safety checks are included. The visit length is therefore longer than the time you spend receiving laser pulses.
The procedure is generally painless, although you may notice mild tingling, slight pressure, a pinch, soreness, burning, or a stinging sensation. Tell the clinician if the sensation is more than you expected.
The clinician may treat one eye at a time. Ask whether both eyes will be treated on separate visits, what pressure checks are planned, and whether you should continue your usual glaucoma drops on the day of treatment. Follow the instructions given for your own eyes rather than changing medicines on your own.
What recovery may feel like in the first few days
Recovery after selective laser trabeculoplasty may include blurred vision, redness, light sensitivity, scratchiness, irritation, soreness, or discomfort. Your vision may be blurry for a couple of hours, so plan to have someone drive you home. These short-term effects typically resolve within a few days.
Minor inflammation usually follows SLT, resolves on its own, and may contribute to the pressure-lowering effect. In one LiGHT study analysis, 241 of 633 patients, or 38.1%, reported temporary blurred vision, discomfort, light sensitivity, or redness. That percentage describes the study group and its recorded symptoms, not a guarantee that you will have them.
Drop instructions after SLT vary between treatment protocols. Some sources describe anti-inflammatory drops for a couple of days. Other instructions describe continuing your existing glaucoma drops and receiving an additional drop only if discomfort occurs; most patients in that source did not feel they needed the extra drop.
Follow your ophthalmologist’s specific instructions. Do not stop glaucoma medicine because your eye feels comfortable. Comfort does not confirm that pressure is controlled.
Inflammation after selective laser trabeculoplasty typically appears within 2–3 days and generally resolves within 5 days in the cited LiGHT study analysis. Temporary blurred vision, light sensitivity, discomfort, and redness are usually self-limiting and typically resolve within several days. Symptoms that become severe, increase, or fail to settle belong in the urgent-help plan described later.

How follow-up shows whether treatment is working
Follow-up visits show whether your pressure is moving toward its target and whether your optic nerve remains stable. The benchmark schedule includes an eye-pressure check immediately before treatment, another check within 30 minutes to 2 hours afterward, and a follow-up examination within 6 weeks or sooner when there is concern about pressure-related optic-nerve damage.
Your clinician may check pressure within 30 minutes to two hours after SLT or during a one-hour post-treatment check. The exact timing depends on your examination findings and the treatment setting. Keep the scheduled checks even if your vision feels normal.
Eye pressure may take up to 6 to 8 weeks to fully decrease after laser trabeculoplasty. If pressure is still too high three months after surgery, you may need more treatment.
For most eyes, one SLT treatment’s effect may last 2 to 3 years, sometimes longer. The effect can wear off after several years, and repeat laser treatment may be possible if the first treatment worked. SLT may have no effect in some eyes, while the effect in other eyes may be marked and last for multiple years.
You may or may not still need glaucoma drops after SLT. Keep follow-up visits and testing so your eye doctor can assess pressure, treatment response, and disease progression.
Ask your eye doctor how success will be measured in your case. Useful questions include:
- What pressure range is my target, and what findings set that target?
- When will you check my pressure after treatment?
- How long will you wait for the full response before considering another treatment?
- Should I continue each of my current drops?
- If pressure remains above target, would you add drops, repeat laser, or consider another procedure?
Ongoing management remains necessary after SLT because pressure, treatment response, and glaucoma progression still need assessment.

What benefits and limitations the evidence shows
The LiGHT trial compared initial selective laser trabeculoplasty with initial eye drops in people with open-angle glaucoma or ocular hypertension. The trial enrolled 718 patients; 356 received SLT and 362 received eye drops. At 36 months, 652 patients, or 91% of those enrolled, returned the primary outcome questionnaire.
At 36 months, 74.2% of patients who received initial SLT required no drops to keep eye pressure at target. Eye pressure was within target at 93.0% of visits after initial laser treatment and 91.3% of visits with initial drops. Pressure-lowering glaucoma surgery was required in none of the initial laser group and 11 patients in the initial eye-drop group.
At six years, 94.2% of eyes initially treated with SLT and 94.7% of eyes initially treated with medication were at target. Target pressure was reached at office visits in 92.8% and 93.2% of cases, respectively. These results show close outcomes in that report, not a universal result for every treatment setting.
SLT lowers eye pressure in about 80% of patients and by as much as 20–30%, on average. The same treatment does not work equally well in every eye. The effect can deteriorate with time, and some people do not respond.
The useful benefit may be less reliance on drops for some people, but SLT is not a cure for glaucoma. You still need pressure checks, optic-nerve monitoring, and visual-field testing as advised.

Common effects and uncommon complications to know
Common short-term effects after SLT include blurred vision, discomfort, light sensitivity, redness, scratchiness, and irritation. In one LiGHT study analysis, 241 of 633 patients, or 38.1%, reported temporary symptoms. A temporary rise in eye pressure occurred after 1% of SLT treatments in a study summary.
The temporary pressure rise may occur within hours after treatment and is usually managed with additional drops or oral medicine. Your clinician may check pressure soon after treatment because the timing of this possible change matters. Mild inflammation, redness, and blurred vision generally settle over several days.
Serious complications are rare, but reported complications include bleeding in the eye, corneal swelling, cystoid macular edema, persistent inflammation, and other eye damage. Rare reports also describe choroidal effusion, foveal burns, and refractive shifts. Cystoid macular edema has been reported in people with predisposing factors such as vein occlusion or prior cataract surgery.
One report found anterior-chamber inflammation in 65 eyes, or 1%, after SLT. The same reported series found hyphema, which is bleeding in the front of the eye, in 12 eyes, or 0.2% of all SLTs. Measurable bleeding occurred in 4 eyes, or 0.07%. Two cases had temporary eye-pressure spikes of 30 to 31 mmHg.
Corneal complications, including swelling and Descemet’s folds, occurred in 6 eyes, or 0.1%, in one report. Four of those eyes had high myopia. In the reported series, permanent vision loss occurred in less than 0.2 per 1,000 treatments and in less than 1 in 4,600 treated eyes.
These figures come from particular reports with their own patient groups and methods. They describe reported frequency, not a personal prediction. Tell your eye doctor about high myopia, prior eye surgery, inflammation, or other eye conditions before treatment so those factors can be included in the decision.
Do not judge the treatment only by whether the first day feels comfortable. Pressure can change without a noticeable symptom, which is why the planned pressure check and later examination matter.
How laser compares with drops and other treatments
Glaucoma treatment can use laser treatment, medication, incisional surgery, or a combination. The comparison below highlights practical trade-offs among these options.
| Option | How it lowers pressure | Practical points and limitations |
|---|---|---|
| Selective laser trabeculoplasty | Stimulates the drainage tissue so fluid can leave the eye more easily. | It may be used first or added to drops. Some people still need drops, and the effect may fade or be absent. Repeat treatment may be possible if the first treatment worked. |
| Pressure-lowering eye drops | Medication lowers eye pressure through its drug effect. | Prostaglandin analogues are described as a standard initial medication option, taken once daily. Missed doses can limit success, and medication side effects remain part of the discussion. |
| Argon laser trabeculoplasty | A thermal laser treats the drainage angle. | Argon treatment may cause more scarring than SLT and may be harder to repeat. |
| Micropulse or direct selective laser trabeculoplasty | Micropulse treatment delivers energy in small pulses; direct selective treatment uses a non-contact, image-guided approach. | Selective, direct selective, argon, and micropulse laser treatments have comparable pressure-lowering results, while their tissue effects and practical steps differ. |
SLT does not affect eligibility for or success rates of other medical or surgical glaucoma treatments. That means choosing laser now does not by itself remove later treatment options.
Some trials report similar pressure lowering with SLT and prostaglandin analogues, while other trials report greater efficacy with prostaglandin analogues. In the LiGHT trial, initial SLT was associated with no drops for target pressure in 74.2% of patients at 36 months, but that finding does not mean every person can stop medication.
Ask your eye doctor to compare the options using your pressure target, glaucoma type, drainage-angle findings, likelihood of responding, ability to use drops as prescribed, and follow-up plan. A choice that reduces daily medication may still require repeated examinations and later treatment.
Why there is no single first choice for everyone
Selective laser trabeculoplasty and glaucoma drops are both evidence-based first-line options, but no single choice fits every patient. Some clinical studies have found initial laser treatment equivalent to or better than medication. A 2019 report argued that SLT should be offered first instead of pressure-lowering drops, but that was a reported position from that year rather than a universal instruction for your care.
In one randomized comparison of about 50 patients, pressure fell from about 25 mmHg to 18.2 mmHg after SLT and to 17.7 mmHg with medication. Pressure reduction did not differ statistically between the groups. The small study result does not establish that the treatments work identically for every type of glaucoma.
Medication may fit your plan when a predictable daily regimen is practical or when your doctor expects drops to provide the pressure reduction you need. Prostaglandin analogues are described as generally well tolerated, taken once daily, and effective at lowering pressure. Missed doses can limit the success of drops, and medication toxicity is a risk to consider.
Laser may fit your plan when your drainage angle is visible, the tissue findings support treatment, and reducing daily drops is a meaningful goal. Laser still has possible pressure spikes, temporary symptoms, variable response, and a need for follow-up. Access to follow-up and your ability to return for pressure checks also belong in the discussion.
Use your examination findings and treatment goals to make the choice with your eye doctor. Do not treat a study average, a treatment pattern, or a general recommendation as a personal prescription.
Treatment patterns in one study population
Selective laser trabeculoplasty (SLT) is one of the standard treatments for open-angle glaucoma. Treatment patterns in one study do not tell you who should receive it. They show who received treatment in a particular population and time period.
One study included 194,759 patients. Women were more likely than men to receive laser trabeculoplasty, while patients aged 81 years or older were less likely to receive it than patients aged 66–70 years. The study also found that patients with prior cataract, corneal-transplant, or retina surgery were less likely to receive laser treatment. These are treatment-pattern findings, not candidacy rules.
Another study found that people receiving frontline laser treatment were typically younger and female, but age and sex did not distinguish people who responded from those who did not. Your age or sex alone does not establish whether laser treatment will lower your pressure.
The diagnoses represented among treated eyes also varied by study. In one study population, primary open-angle glaucoma accounted for 45% of treated eyes, normal-tension glaucoma for 22%, and exfoliation glaucoma for 20%. In another report, participants had a median age of 71; 65% were women and 98% were White. Those figures describe the study population, not your eligibility or expected response.
High myopia was present in 14% of eyes in one study. Clinicians may adjust SLT when complication risk is slightly elevated. Tell your eye doctor about your prescription strength and prior procedures so the examination can guide the plan.

Symptoms that need urgent qualified help
Severe or increasing eye pain, marked redness, sudden or substantial vision loss, or symptoms that worsen rather than settle require urgent assessment. Do not wait for a scheduled follow-up when these signs occur.
Take your prescribed glaucoma medicine unless your clinician tells you to stop. Feeling comfortable does not confirm that your eye pressure is controlled. If you have an ocular emergency, Northwest Eye requests that you do not use its contact form; seek urgent qualified eye care instead.
Before treatment, contact your eye-care professional promptly if new or worsening eye symptoms make you question whether the procedure should proceed. Keep the exact symptom combination clear when you call or seek care.
Questions to bring to your eye-care discussion
Your eye-care discussion should connect the examination findings to a specific pressure goal and follow-up plan. Bring these questions:
- Is my glaucoma open-angle, and can you see my drainage angle clearly?
- What did gonioscopy show about my trabecular meshwork and its pigmentation?
- What pressure range are we targeting, and why?
- Would laser be initial treatment, an add-on to drops, or a later option?
- How much of the drainage angle would you treat?
- What sensations, temporary symptoms, and drop instructions should I expect?
- When will you check my pressure after treatment, and when will you judge the full response?
- If the response is incomplete or fades, would you use drops, repeat laser, or another surgery?
- Which symptoms should lead me to seek urgent assessment?
A qualified eye-care professional must decide whether laser treatment fits your examination findings, pressure target, glaucoma type, and treatment goals. If you want to discuss those questions in person, book an eye exam at Northwest Eye in Minnetonka.
Frequently asked questions about laser trabeculoplasty
When should I seek urgent help after laser trabeculoplasty?
Seek urgent assessment for severe or increasing eye pain, marked redness, sudden or substantial vision loss, or symptoms that worsen instead of settling. Do not wait for a scheduled follow-up. Continue prescribed glaucoma medicine unless your clinician tells you otherwise, and do not assume that feeling comfortable means your eye pressure is controlled.
How common is laser trabeculoplasty, and who usually receives it?
Laser trabeculoplasty is a standard treatment for open-angle glaucoma, but treatment patterns do not determine personal eligibility. In one study of 194,759 patients, women were more likely than men to receive it, and patients aged 81 or older were less likely than those aged 66–70. Age and sex did not predict treatment response.
Can laser trabeculoplasty be repeated if the first treatment wears off?
Repeat treatment may be possible when the first procedure lowered pressure effectively and its benefit later fades. One treatment’s effect may last 2 to 3 years, sometimes longer, but responses vary and some eyes do not respond. Your eye doctor must reassess pressure, the drainage tissue, and the need for drops or another procedure.
Will I still need glaucoma drops after the procedure?
You may still need glaucoma drops after treatment because laser trabeculoplasty is not a cure and does not lower pressure enough for every eye. Follow your ophthalmologist’s specific instructions, since post-treatment drop plans vary. Do not stop existing medicine because your eye feels comfortable; pressure can change without noticeable symptoms.





